Danaher Co. (NYSE:DHR) Stock Position Lowered by Regent Investment Management LLC

Regent Investment Management LLC lessened its position in Danaher Co. (NYSE:DHRGet Rating) by 1.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,500 shares of the conglomerate’s stock after selling 114 shares during the period. Regent Investment Management LLC’s holdings in Danaher were worth $1,901,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of DHR. US Asset Management LLC grew its holdings in shares of Danaher by 0.6% in the 1st quarter. US Asset Management LLC now owns 5,774 shares of the conglomerate’s stock worth $1,694,000 after acquiring an additional 37 shares during the last quarter. Mairs & Power Inc. grew its holdings in shares of Danaher by 4.1% in the 4th quarter. Mairs & Power Inc. now owns 959 shares of the conglomerate’s stock worth $316,000 after acquiring an additional 38 shares during the last quarter. Mutual Advisors LLC grew its holdings in shares of Danaher by 0.7% in the 4th quarter. Mutual Advisors LLC now owns 5,792 shares of the conglomerate’s stock worth $1,906,000 after acquiring an additional 40 shares during the last quarter. Encompass Wealth Advisors LLC grew its holdings in shares of Danaher by 1.9% in the 1st quarter. Encompass Wealth Advisors LLC now owns 2,292 shares of the conglomerate’s stock worth $672,000 after acquiring an additional 42 shares during the last quarter. Finally, Howe & Rusling Inc. grew its holdings in shares of Danaher by 48.8% during the first quarter. Howe & Rusling Inc. now owns 128 shares of the conglomerate’s stock valued at $38,000 after buying an additional 42 shares in the last quarter. Institutional investors own 77.27% of the company’s stock.

Analysts Set New Price Targets

DHR has been the topic of a number of research analyst reports. Evercore ISI lowered their price target on Danaher from $320.00 to $280.00 and set an “outperform” rating on the stock in a report on Tuesday, July 5th. Cowen lowered their price target on Danaher to $340.00 in a report on Friday, July 22nd. Benchmark lowered their price target on Danaher from $345.00 to $325.00 and set a “buy” rating on the stock in a report on Tuesday. Royal Bank of Canada lifted their price target on Danaher from $317.00 to $318.00 and gave the company an “outperform” rating in a report on Friday, September 16th. Finally, StockNews.com upgraded Danaher from a “buy” rating to a “strong-buy” rating in a report on Friday, August 26th. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $321.75.

Danaher Stock Down 1.6 %

Shares of NYSE:DHR traded down $4.15 on Friday, reaching $262.28. The company had a trading volume of 62,701 shares, compared to its average volume of 2,203,832. Danaher Co. has a twelve month low of $233.71 and a twelve month high of $331.68. The stock has a 50-day moving average price of $280.99 and a 200 day moving average price of $269.91. The stock has a market capitalization of $190.80 billion, a P/E ratio of 31.38, a P/E/G ratio of 1.29 and a beta of 0.88. The company has a quick ratio of 1.32, a current ratio of 1.75 and a debt-to-equity ratio of 0.45.

Danaher (NYSE:DHRGet Rating) last posted its quarterly earnings data on Thursday, July 21st. The conglomerate reported $2.76 earnings per share for the quarter, topping the consensus estimate of $2.35 by $0.41. Danaher had a return on equity of 18.57% and a net margin of 20.61%. The business had revenue of $7.75 billion during the quarter, compared to analysts’ expectations of $7.29 billion. During the same quarter in the previous year, the firm earned $2.46 EPS. The firm’s revenue was up 7.4% compared to the same quarter last year. On average, equities analysts expect that Danaher Co. will post 10.4 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 30th will be given a dividend of $0.25 per share. The ex-dividend date is Thursday, September 29th. This represents a $1.00 dividend on an annualized basis and a yield of 0.38%. Danaher’s dividend payout ratio (DPR) is presently 11.78%.

Insider Buying and Selling

In related news, Director Walter G. Lohr sold 3,906 shares of the stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $273.84, for a total transaction of $1,069,619.04. Following the sale, the director now directly owns 12,115 shares in the company, valued at approximately $3,317,571.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Danaher news, CEO Rainer Blair sold 25,000 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $300.00, for a total transaction of $7,500,000.00. Following the transaction, the chief executive officer now owns 79,739 shares of the company’s stock, valued at approximately $23,921,700. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Walter G. Lohr sold 3,906 shares of the company’s stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $273.84, for a total value of $1,069,619.04. Following the transaction, the director now directly owns 12,115 shares in the company, valued at approximately $3,317,571.60. The disclosure for this sale can be found here. Insiders have sold a total of 40,906 shares of company stock worth $11,823,179 in the last three months. Insiders own 11.20% of the company’s stock.

Danaher Company Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRGet Rating).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.